Skip to main content

nisevokitug

Generic: Nisevokitug

nisevokitug: 2 clinical trials tracked.

nisevokitug evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about nisevokitug, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)

NCT04952753Registry updated 2025-03-26·Phase 2
Terminated

Primary endpoint: Safety run-in: Percentage of participants with dose limiting toxicities (DLTs) during the first cycle (4 weeks) of treatment.

InterventionalRandomizedopen204 targetStarted 2021-11Completion 2025-0150 sites · Australia, Belgium, Canada, Czechia…Novartis Pharmaceuticals

A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

NCT04935359Registry updated 2026-05-19·Phase 3
Completed

Primary endpoint: Safety run-in Part: Percentage of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment.

InterventionalRandomizedquadruple511 enrolledStarted 2021-09Completion 2024-0850 sites · Australia, Belgium, Brazil, Canada…Novartis Pharmaceuticals